Bharat Biotech’s Covaxin Gets Nod For Next Phase Of Trials On 2-18 Years Old

New Delhi: Bharat Biotech’s Covid-19 vaccine Covaxin got approved by an expert panel on Tuesday for phase II and III human clinical trials on those between 2-18 years of age.

The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organization (CDSCO) discussed upon Bharat Biotech’s application seeking permission to conduct the next phase of clinical trials to assess the safety of Covaxin jabs in children aged 2 to 18 years.

According to reports, the first wave of the virus attacked the elderly, in the second wave more youth have been affected and in the the third wave children of this age are more likely to be at risk. Amid these reports the decision has been made as an advanced precautionary measure. 

The trial will take place in 525 subjects at various sites, including AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences Nagpur, added reports.

Covaxin has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) which is being used in adults in India’s ongoing Covid-19 vaccination drive.